World's Best Scientists 2026 revealed!
Elizabeth R. Plimack

Elizabeth R. Plimack

D-Index & Metrics

Medicine

D-Index
83
Citations
52539
World Ranking
15339
National Ranking
7735

Elizabeth R. Plimack publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Elizabeth R. Plimack sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 652 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Elizabeth R. Plimack D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Elizabeth R. Plimack sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Elizabeth R. Plimack is affiliated with the Fox Chase Cancer Center in the United States. Their research spans the field of Medicine, with a significant focus on Surgery, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, and Cancer Research. The predominant areas of study include Bladder and Urothelial Cancer Treatments, Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Urinary and Genital Oncology Studies, Renal and related cancers, Economic and Financial Impacts of Cancer, and Cancer Genomics and Diagnostics.

Among the notable recent papers associated with Elizabeth R. Plimack are:

  • Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial, 2020, The Lancet Oncology
  • Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, 2020, ESMO Open
  • Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial, 2020, Cancer

Elizabeth R. Plimack has frequently collaborated with several coauthors, including:

  • Brian I. Rini
  • Toni K. Choueiri
  • David F. McDermott
  • Daniel M. Geynisman
  • Hans J. Hammers

Their work has been regularly published in leading academic journals, notably:

  • Journal of Clinical Oncology
  • Cancer
  • European Urology
  • Annals of Oncology
  • European Urology Oncology

Elizabeth R. Plimack's contributions cover a wide spectrum of oncology research, especially focusing on cancer immunotherapy, renal cancers, and treatment guidelines. Their publications reflect involvement in significant clinical trials and guideline development pertinent to bladder and kidney cancers.

Best Publications

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov

  • Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

    Razvan Cristescu;Robin Mogg;Mark Ayers;Andrew Albright

  • Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

    Padmanee Sharma;Margitta M. Retz;Arlene Siefker-Radtke;Ari D. Baron

  • Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

    Woonyoung Choi;Sima Porten;Seungchan Kim;Daniel Willis

  • First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

    Arjun V Balar;Daniel Castellano;Peter H O'Donnell;Petros Grivas

  • Prostate cancer. Clinical practice guidelines in oncology.

    James Mohler;Robert R. Bahnson;Barry Boston;J. Erik Busby

  • Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

    James L. Mohler;Emmanuel S. Antonarakis;Andrew J. Armstrong;Anthony V. D'Amico

  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    Christos E. Kyriakopoulos;Yu Hui Chen;Michael A. Carducci;Glenn Liu

  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

  • Prostate Cancer, Version 1.2016

    James L. Mohler;Andrew J. Armstrong;Robert R. Bahnson;Anthony Victor D'Amico

  • Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

    Thomas Powles;Elizabeth R Plimack;Denis Soulières;Tom Waddell

  • Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

    Robert J Motzer;Eric Jonasch;Neeraj Agarwal;Sam Bhayani

  • Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

    Elizabeth R. Plimack;Roland L. Dunbrack;Timothy A. Brennan;Mark D. Andrake

  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

    Laurence Albiges;Nizar M. Tannir;Mauricio Burotto;David McDermott;David McDermott

  • Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

    Hans J. Hammers;Elizabeth R. Plimack;Jeffrey R. Infante;Brian I. Rini

  • Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology

    James L. Mohler;Philip W. Kantoff;Andrew J. Armstrong;Robert R. Bahnson

  • Bladder cancer. Clinical practice guidelines in oncology.

    Peter E. Clark;Neeraj Agarwal;Matthew C. Biagioli;Mario A. Eisenberger

Frequent Co-Authors

David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Thomas Powles
Thomas Powles Queen Mary University of London
Robert G. Uzzo
Robert G. Uzzo Fox Chase Cancer Center
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Jonathan E. Rosenberg
Jonathan E. Rosenberg Memorial Sloan Kettering Cancer Center
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Dean F. Bajorin
Dean F. Bajorin Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in healthcare beyond traditional medical school, there are a variety of affordable and flexible online degree options to consider. These programs can lead to diverse career paths in healthcare leadership, advanced practice, and pharmacy—each offering unique benefits for students with different professional goals.

For those who want to lead healthcare organizations or move into administrative roles, many universities offer some of the best online mha programs. These Master of Healthcare Administration (MHA) degrees emphasize leadership, health policy, and management skills. If affordability is a top priority, explore the cheapest online mha options to minimize tuition without compromising quality.

For nurses seeking to become nurse practitioners or move into advanced clinical roles, the cheapest dnp programs online are tailored for working professionals and help students advance their practice while allowing them to balance their careers and studies.

Interested in pharmacy or pharmaceutical research? There are pathways to earn a pharmacy degree online, equipping you with essential knowledge in drug therapy and patient safety.

No matter your goals, these online healthcare degrees provide both affordability and flexibility—key factors when planning your career in medicine and health sciences.

Best Scientists Citing Elizabeth R. Plimack

Trending Scientists

Recently Published Articles